Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.

INTRODUCTION: The objective of this report is to describe the clinical pathway for early treatment of patients with acute SARS-CoV-2 infection and to evaluate the first results of its implementation. METHODS: This is a descriptive and retrospective study of the implementation of a clinical pathway o...

ver descrição completa

Detalhes bibliográficos
Autores: Pinargote-Celorio H, Otero-Rodríguez S, González-de-la-Aleja P, Rodríguez-Díaz JC, Climent E, Chico-Sánchez P, Riera G, Llorens P, Aparicio M, Montiel I, Boix V, Moreno-Pérez Ó, Ramos-Rincón JM, Merino E
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p9392
Acesso em linha:https://isabial.portalinvestigacion.com/publicaciones9392
Access Level:acceso abierto
Palavra-chave:COVID-19
SARS-CoV-2
clinical pathway
nirmatrelvir/ritonavir
non-hospitalized treatment COVID-19
remdesivir
sotrovimab
id ES_c28fa0dc29ad58c117d9a6093ec03b96
oai_identifier_str oai:isabial.fundanetsuite.com:p9392
network_acronym_str ES
network_name_str España
repository_id_str
spelling Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.Pinargote-Celorio HOtero-Rodríguez SGonzález-de-la-Aleja PRodríguez-Díaz JCCliment EChico-Sánchez PRiera GLlorens PAparicio MMontiel IBoix VMoreno-Pérez ÓRamos-Rincón JMMerino ECOVID-19SARS-CoV-2clinical pathwaynirmatrelvir/ritonavirnon-hospitalized treatment COVID-19remdesivirsotrovimabINTRODUCTION: The objective of this report is to describe the clinical pathway for early treatment of patients with acute SARS-CoV-2 infection and to evaluate the first results of its implementation. METHODS: This is a descriptive and retrospective study of the implementation of a clinical pathway of treatment in outpatients (January 1 to June 30 2022). Clinical pathway: detection and referral systems from Primary Care, Emergency services, hospital specialities and an automated detection system; clinical evaluation and treatment administration in the COVID-19 day-hospital and subsequent clinical follow-up. Explanatory variables: demographics, comorbidity, vaccination status, referral pathways and treatment administration. OUTCOME VARIABLES: hospitalization and death with 30 days, grade 2-3 toxicity related to treatment. RESULTS: Treatment was administered to 262 patients (53,4% women, median age 60 years). The treatment indication criteria were immunosupression (68,3%), and the combination of age, vaccination status and comorbidity in the rest47,3% of the patients s received remdesivir, 35,9% nirmatrelvir/ritonavir, 13,4% sotrovimab and 2,4% combined treatment with a median of 4 days after symptom onset. Hospital admission was required for 6,1% of the patients, 3,8% related to progression COVID-19. No patient died. Toxicity grade 2-3 toxicity was reported in 18,7%, 89,8% dysgeusia and metallic tasted related nirmatrelvir/ritonavir. Seven patients discontinued treatment due to toxicity. CONCLUSION: The creation and implementation of a clinical pathway for non-hospitalized patients with SARS-CoV-2 infection is effective and it allows early accessibility and equity of currently available treatments.EDICIONES DOYMA S A2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones9392ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICAISSN: 0213005XISSNe: 15781852reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Españolinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p93922026-06-12T10:20:37Z
dc.title.none.fl_str_mv Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.
title Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.
spellingShingle Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.
Pinargote-Celorio H
COVID-19
SARS-CoV-2
clinical pathway
nirmatrelvir/ritonavir
non-hospitalized treatment COVID-19
remdesivir
sotrovimab
title_short Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.
title_full Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.
title_fullStr Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.
title_full_unstemmed Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.
title_sort Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz.
dc.creator.none.fl_str_mv Pinargote-Celorio H
Otero-Rodríguez S
González-de-la-Aleja P
Rodríguez-Díaz JC
Climent E
Chico-Sánchez P
Riera G
Llorens P
Aparicio M
Montiel I
Boix V
Moreno-Pérez Ó
Ramos-Rincón JM
Merino E
author Pinargote-Celorio H
author_facet Pinargote-Celorio H
Otero-Rodríguez S
González-de-la-Aleja P
Rodríguez-Díaz JC
Climent E
Chico-Sánchez P
Riera G
Llorens P
Aparicio M
Montiel I
Boix V
Moreno-Pérez Ó
Ramos-Rincón JM
Merino E
author_role author
author2 Otero-Rodríguez S
González-de-la-Aleja P
Rodríguez-Díaz JC
Climent E
Chico-Sánchez P
Riera G
Llorens P
Aparicio M
Montiel I
Boix V
Moreno-Pérez Ó
Ramos-Rincón JM
Merino E
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
SARS-CoV-2
clinical pathway
nirmatrelvir/ritonavir
non-hospitalized treatment COVID-19
remdesivir
sotrovimab
topic COVID-19
SARS-CoV-2
clinical pathway
nirmatrelvir/ritonavir
non-hospitalized treatment COVID-19
remdesivir
sotrovimab
description INTRODUCTION: The objective of this report is to describe the clinical pathway for early treatment of patients with acute SARS-CoV-2 infection and to evaluate the first results of its implementation. METHODS: This is a descriptive and retrospective study of the implementation of a clinical pathway of treatment in outpatients (January 1 to June 30 2022). Clinical pathway: detection and referral systems from Primary Care, Emergency services, hospital specialities and an automated detection system; clinical evaluation and treatment administration in the COVID-19 day-hospital and subsequent clinical follow-up. Explanatory variables: demographics, comorbidity, vaccination status, referral pathways and treatment administration. OUTCOME VARIABLES: hospitalization and death with 30 days, grade 2-3 toxicity related to treatment. RESULTS: Treatment was administered to 262 patients (53,4% women, median age 60 years). The treatment indication criteria were immunosupression (68,3%), and the combination of age, vaccination status and comorbidity in the rest47,3% of the patients s received remdesivir, 35,9% nirmatrelvir/ritonavir, 13,4% sotrovimab and 2,4% combined treatment with a median of 4 days after symptom onset. Hospital admission was required for 6,1% of the patients, 3,8% related to progression COVID-19. No patient died. Toxicity grade 2-3 toxicity was reported in 18,7%, 89,8% dysgeusia and metallic tasted related nirmatrelvir/ritonavir. Seven patients discontinued treatment due to toxicity. CONCLUSION: The creation and implementation of a clinical pathway for non-hospitalized patients with SARS-CoV-2 infection is effective and it allows early accessibility and equity of currently available treatments.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones9392
url https://isabial.portalinvestigacion.com/publicaciones9392
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv EDICIONES DOYMA S A
publisher.none.fl_str_mv EDICIONES DOYMA S A
dc.source.none.fl_str_mv ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
ISSN: 0213005X
ISSNe: 15781852
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418697644310528
score 15,812455

Registos relacionados